INO Inovio Pharmaceuticals (INO) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001055726
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
49
13F, latest reported quarter
Conversions, 180 days
8
Codes C/M, not in net · no price filed
Inovio Pharmaceuticals insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for INOVIO PHARMACEUTICALS, INC. in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on May 16, 2022.
- The trade is 10.8% of the 52,716 shares held after it.
- No other insider sold within 30 days.
- 49 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Zoth Lota S. sold about $3.2K of INO on Jun 5, 2023; 49 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Feb 27, 2023.
- The trade is 0.6% of the 910,124 shares held after it.
- No other insider sold within 30 days.
- 49 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Weiner David B. sold about $6.7K of INO on Mar 13, 2023; 49 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Aug 11, 2022.
- The trade is 1.3% of the 904,291 shares held after it.
- No other insider sold within 30 days.
- 49 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Weiner David B. sold about $14.9K of INO on Feb 27, 2023; 49 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on May 16, 2022.
- The trade is 1.3% of the 892,625 shares held after it.
- 1 other insider sold within 30 days.
- 49 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Weiner David B. sold about $31.6K of INO on Aug 11, 2022, the largest insider sale at the company since 2021; 1 other insider sold within 30 days and 49 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Mar 16, 2022.
- The trade is 2.7% of the 75,305 shares held after it.
- 1 other insider sold within 30 days.
- 49 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director BENITO SIMON X sold about $4.5K of INO on Jul 20, 2022; 1 other insider sold within 30 days and 49 funds added in the latest 13F quarter.13 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
49 funds bought in last quarter
below 54% of Pharma & Biotech
Revenue
-70.0% year over year
below 85% of Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
21.7% of the float short (float per yahoo 2026-10-26) · 7.6 days to cover · settled 2026-09-30
more than 94% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch INO
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-59.5%12M
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns INO: institutional holders (13F)
13F holdings, latest reported quarter
8,454,797 sh
$9.3M
5,171,053 sh
$5.7M
3,650,562 sh
$4.0M
2,844,994 sh
$3.1M
2,143,910 sh
$2.4M
Congress trades in INO
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
INO planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
INO mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Fund
$190.3K position · as of 2026-06-30
0.2%
Fidelity Small Cap Growth Fund
$4.7M position · as of 2026-07-31
0.1%
Fidelity Small Cap Growth K6 Fund
$2.4M position · as of 2026-07-31
0.1%
iShares Micro-Cap ETF
$308.2K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$20.8K position · as of 2026-06-30
0.0%
TIFF MULTI-ASSET FUND
$23.7K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
9 registered trials, 1 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
3
Phase 2
0 active
2
Phase 3
0 active
4
Multi-phase
1 active
What changed recently
INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (
2026-10-23 · Completion moved 2026-12-31 → 2027-12-31
PHASE1,PHASE2
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 49 funds added last quarter. Each figure is a federal filing, dated the day it went public.
INO financials
Revenue growth
-70.0%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$0
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM INO
| FY Dec 2025 | $65.3K |
| FY Dec 2024 | $217.8K |
| FY Dec 2023 | $832.0K |
| FY Dec 2022 | $10.3M |
| FY Dec 2021 | $1.8M |
| Jun 2026 | $0 |
| Mar 2026 | $0 |
| Dec 2025 | $0 |
| Sep 2025 | $0 |
| Jun 2025 | $0 |
| Mar 2025 | $65.3K |
| Dec 2024 | $117.0K |
| Sep 2024 | $0 |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Net margin, TTM INO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -2,727% |
| FY Dec 2021 | -17,110% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$80.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM INO
| FY Dec 2025 | -$88.9M |
| FY Dec 2024 | -$104.6M |
| FY Dec 2023 | -$124.7M |
| FY Dec 2022 | -$217.2M |
| FY Dec 2021 | -$216.9M |
| Jun 2026 | -$18.0M |
| Mar 2026 | -$21.6M |
| Dec 2025 | -$19.5M |
| Sep 2025 | -$21.6M |
| Jun 2025 | -$20.8M |
| Mar 2025 | -$26.9M |
| Dec 2024 | -$19.7M |
| Sep 2024 | -$27.4M |
At each fiscal year end
Single quarter
Debt to equity
0.00x
long-term debt only, 2023-12-31 (30 months older than the period end); equity 2026-06-30
Debt to equity INO
| FY Dec 2025 | 0.00x |
| FY Dec 2024 | 0.00x |
| FY Dec 2023 | 0.00x |
| FY Dec 2022 | 0.07x |
| FY Dec 2021 | 0.16x |
| Jun 2026 | 0.00x |
| Mar 2026 | 0.00x |
| Dec 2025 | 0.00x |
| Sep 2025 | n/a |
| Jun 2025 | 0.00x |
| Mar 2025 | 0.00x |
| Dec 2024 | 0.00x |
| Sep 2024 | 0.00x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt to cover
Cash flow to debt INO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -13.01x |
| FY Dec 2021 | -3.44x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-410.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity INO
| FY Dec 2025 | -183.6% |
| FY Dec 2024 | -115.1% |
| FY Dec 2023 | -79.5% |
| FY Dec 2022 | -90.0% |
| FY Dec 2021 | -70.6% |
| Jun 2026 | -410.2% |
| Mar 2026 | -296.5% |
| Dec 2025 | -183.6% |
| Sep 2025 | -327.7% |
| Jun 2025 | -139.7% |
| Mar 2025 | -132.1% |
| Dec 2024 | -115.1% |
| Sep 2024 | -106.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-114.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets INO
| FY Dec 2025 | -90.7% |
| FY Dec 2024 | -75.3% |
| FY Dec 2023 | -52.0% |
| FY Dec 2022 | -66.3% |
| FY Dec 2021 | -58.6% |
| Jun 2026 | -114.7% |
| Mar 2026 | -124.0% |
| Dec 2025 | -90.7% |
| Sep 2025 | -122.2% |
| Jun 2025 | -86.6% |
| Mar 2025 | -88.9% |
| Dec 2024 | -75.3% |
| Sep 2024 | -75.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital INO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-344.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed INO
| FY Dec 2025 | -160.0% |
| FY Dec 2024 | -109.0% |
| FY Dec 2023 | -75.7% |
| FY Dec 2022 | -78.5% |
| FY Dec 2021 | -64.9% |
| Jun 2026 | -344.6% |
| Mar 2026 | -233.2% |
| Dec 2025 | -160.0% |
| Sep 2025 | -215.9% |
| Jun 2025 | -133.2% |
| Mar 2025 | -127.9% |
| Dec 2024 | -109.0% |
| Sep 2024 | -102.5% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing INO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$61.5M
market value at close 2026-10-23 on 2026-08-10 shares, plus long-term debt only, 2023-12-31 (30 months older than the period end), minus cash 2026-06-30
Enterprise value INO
| FY Dec 2025 | $48.9M |
| FY Dec 2024 | -$18.1M |
| FY Dec 2023 | $1.7B |
| FY Dec 2022 | $4.6B |
| FY Dec 2021 | $12.6B |
| Jun 2026 | $59.0M |
| Mar 2026 | $93.9M |
| Dec 2025 | $48.9M |
| Sep 2025 | $87.8M |
| Jun 2025 | $50.5M |
| Mar 2025 | $19.9M |
| Dec 2024 | -$18.1M |
| Sep 2024 | $128.4M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-86.8%
TTM free cash flow over market value at close 2026-10-23
FCF yield INO
| FY Dec 2025 | -95.4% |
| FY Dec 2024 | -218.9% |
| FY Dec 2023 | -7.5% |
| FY Dec 2022 | -4.7% |
| FY Dec 2021 | -1.7% |
| Jun 2026 | -89.3% |
| Mar 2026 | -69.5% |
| Dec 2025 | -95.4% |
| Sep 2025 | -71.6% |
| Jun 2025 | -126.8% |
| Mar 2025 | -171.8% |
| Dec 2024 | -218.9% |
| Sep 2024 | -74.1% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing INO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $65.3K | $217.8K | $832.0K | $10.3M |
| Operating income | -$86.8M | -$112.4M | -$143.9M | -$267.6M |
| Net income | -$85.0M | -$107.0M | -$135.0M | -$279.8M |
| EPS (diluted) | -1.81 | -3.95 | -6.09 | -14.07 |
| Operating cash flow | -$88.6M | -$104.1M | -$124.4M | -$216.2M |
| Cash | $44.3M | $65.8M | $14.3M | $46.3M |
| Long-term debt | n/a | n/a | $0 | $16.6M |
SEC XBRL, fiscal years, as known on 2026-10-27
INO Stock Sonar score 5/7 axes
Find similar shapesCompareINO ranks highest on financial health (99th percentile) and institutional and government (46th), and lowest on profitability (12th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
